These ranges are research planning, not personal dosing recommendations, and no published human Phase 2 or Phase 3 dose-finding trial exists
The estimated oral dose range from animal research is approximately 18 mg/kg, but human pharmacokinetic parameters including bioavailability fraction, Tmax, and clearance remain entirely unknown
Gutirrez-Rojas I, Lozano D, Nuche-Berenguer B, et al
Following a standardized process reduces the risk of contamination and ensures the tirzepatide remains potent
Reduction of Abdominal and Visceral Fat : Animal and early human models have demonstrated a preferential reduction of abdominal fat following subcutaneous administration of AOD-9604
34.8%) by regulating Treg function and stabilizing the microbiota